Heparan sulfate mediates trastuzumab effect in breast cancer cells.

ABSTRACT:

Background

Trastuzumab is an antibody widely used in the treatment of breast cancer cases that test positive for the human epidermal growth factor receptor 2 (HER2). Many patients, however, become resistant to this antibody, whose resistance has become a major focus in breast cancer research. But despite this interest, there are still no reliable markers that can be used to identify resistant patients. A possible role of several extracellular matrix (ECM) components--heparan sulfate (HS), Syn-1(Syndecan-1) and heparanase (HPSE1)--in light of the influence of ECM alterations on the action of several compounds on the cells and cancer development, was therefore investigated in breast cancer cell resistance to trastuzumab.

Methods

The cDNA of the enzyme responsible for cleaving

SUBMITTER: Suarez ER 

PROVIDER: S-EPMC3850728 | biostudies-literature | 2013 Oct

REPOSITORIES: biostudies-literature